HCPCS Level II · Drugs administered other than oral method
J2426Injection, paliperidone palmitate extended release (invega sustenna), 1 mg
✓ Active
Source: CMS HCPCS quarterly update, October 2026. Page updated September 29, 2026.
About J2426
J2426 is an HCPCS Level II code in the J series (drugs administered other than oral method), describing injection, paliperidone palmitate extended release (invega sustenna), 1 mg.
It was added to HCPCS effective 01/01/2011, and its current record took effect 07/01/2023.
Its Medicare coverage code is "C", meaning coverage is left to the Medicare contractor's judgment.
Details
- Short description
- Inj, invega sustenna, 1 mg
- Date added
- 01/01/2011
- Action effective
- 07/01/2023
- BETOS
- O1E
Related J24xx codes
- J2401Injection, chloroprocaine hydrochloride, per 1 mg
- J2402Injection, chloroprocaine hydrochloride (clorotekal), per 1 mg
- J2403Chloroprocaine hcl ophthalmic, 3% gel, 1 mg
- J2404Injection, nicardipine, 0.1 mg
- J2405Injection, ondansetron hydrochloride, per 1 mg
- J2406Injection, oritavancin (kimyrsa), 10 mg
- J2407Injection, oritavancin (orbactiv), 10 mg
- J2410Injection, oxymorphone hcl, up to 1 mg
- J2425Injection, palifermin, 50 micrograms
- J2427Injection, paliperidone palmitate extended release (invega hafyera, or invega trinza), 1 mg
- J2428Injection, paliperidone palmitate extended release (erzofri), 1 mg
- J2430Injection, pamidronate disodium, per 30 mg
Common questions about J2426
Is HCPCS J2426 still valid?
- Yes. J2426 is active in the CMS October 2026 HCPCS file.
Does Medicare cover J2426?
- Its coverage code is "C": coverage is left to the Medicare contractor's judgment. Check the local coverage determination for your region.